MOUNTAIN VIEW, Calif.,
April 16, 2015 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report
results for its fiscal quarter ended March
31, 2015 on Wednesday, May 6,
2015, following the close of the U.S. financial
markets. The Company will also host an investor conference
call and live webcast on the same day at 5:00 p.m. Eastern Time to provide a company
update and discuss the financial results.
To access the webcast via the Internet, go to www.alexza.com,
under the "Investors" link. Please log onto the webcast prior
to the start of the call to ensure time for any software downloads
that may be required to participate in the webcast.
LIVE CALL:
1-877-870-4263 or +1-412-317-0790
(international)
Passcode: Please request the Alexza Pharmaceuticals conference
call
REPLAY:
1-877-344-7529 or +1-412-317-0088
(international)
Passcode: 10063923
A replay of the conference call may also be accessed at
www.alexza.com under the "Investors" link. A replay of the
call will be available for 7 days following the event.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development, and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato® system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE®, Alexza's first commercial product, is based
on the Staccato system and has been approved for sale by the
U.S. Food and Drug Administration, the European Commission,
and in several Latin American countries. ADASUVE is currently
being marketed in twelve EU member countries, the United States, and one country in Latin
America. ADASUVE has been approved in 7 additional countries
in Latin America.
Teva Pharmaceuticals USA, Inc.,
a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza's
commercial partner for ADASUVE in the United States. Grupo
Ferrer Internacional SA is Alexza's commercial partner for ADASUVE
in Europe, Latin America, and the Commonwealth of
Independent States countries.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc. For more
information, please visit www.alexza.com.
Safe Harbor Statement
The anticipated news release
and conference call will contain forward-looking statements that
involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities
Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of
Alexza and its partners, Teva and Ferrer, to effectively and
profitably commercialize ADASUVE, estimated product revenues and
royalties associated with the sale of ADASUVE, the adequacy of the
Company's capital to support the Company's operations, and the
Company's ability to raise additional funds and the potential terms
of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2014 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alexza-to-report-2015-first-quarter-financial-results-and-provide-corporate-update-on-wednesday-may-6-2015-300066809.html
SOURCE Alexza Pharmaceuticals, Inc.